Published Date: 02 Mar 2023
Members of Congress are scrambling to test whether Bayh-Dole's "walk-in" provisions for patents on federally-funded discoveries could lower the cost of certain drugs in the United States.
Read Full NewsDESTINY-Lung04 supports trastuzumab deruxtecan as a new frontline option for patients with advanced HER2-mutant disease, though it failed to improve overall survival.
A European Parliament committee is backing employer risk assessments to tackle burnout. But should that mean new binding EU rules?
High 2-year survival rates are seen in treatment-naive patients with CLL receiving a noncovalent BTK inhibitor combined with venetoclax and obinutuzumab.
Floretyrosine F18 is the first amino acid PET imaging agent approved for glioma in the United States.
1.
Sevabertinib Approved for First-Line Mutated NSCLC
2.
Top 10 questions about breast cancer answered
3.
Inadvertent lung cancer screening results are discussed in a new study.
4.
United States Lung Cancer Screening Rates Remain Low. s. in particular in the South.
5.
Study indicates that exercise can help colon cancer survivors live as long as matched individuals
1.
Red Blood Cell Microparticles: Tiny Warriors Against Bleeding in the Brain
2.
An Analytical and Statistical Journey through Genomic Revolution, Novel Therapeutics, and Future Horizons in Lymphoma 2025
3.
Neoadjuvant Radiotherapy & Endocrine Therapy in ER+ Breast Cancer Treatment
4.
A New Hope: Exploring the Potential of Pegaspargase in Treating Cancer
5.
CA-125 Test: Why It's Important for Women's Health and Early Detection of Ovarian Cancer
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part V
2.
Advances in Classification/ Risk Stratification of Plasma Cell Dyscrasias
3.
What Therapy Would Yield the Best Outcomes In Patients with R/R B-cell ALL?
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II
5.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation